Rapid feedback on hospital onset SARS-CoV-2 infections combining epidemiological and sequencing data

  1. Oliver Stirrup  Is a corresponding author
  2. Joseph Hughes
  3. Matthew Parker
  4. David G Partridge
  5. James G Shepherd
  6. James Blackstone
  7. Francesc Coll
  8. Alexander Keeley
  9. Benjamin B Lindsey
  10. Aleksandra Marek
  11. Christine Peters
  12. Joshua B Singer
  13. The COVID-19 Genomics UK (COG-UK) consortium
  14. Asif Tamuri
  15. Thushan I de Silva
  16. Emma C Thomson
  17. Judith Breuer  Is a corresponding author
  1. University College London, United Kingdom
  2. University of Glasgow, United Kingdom
  3. The University of Sheffield, United Kingdom
  4. Sheffield Teaching Hospitals NHS Foundation Trust, United Kingdom
  5. London School of Hygiene and Tropical Medicine, United Kingdom
  6. NHS Greater Glasgow and Clyde, United Kingdom
  7. MRC-University of Glasgow, United Kingdom

Abstract

Background: Rapid identification and investigation of healthcare-associated infections (HCAIs) is important for suppression of SARS-CoV-2, but the infection source for hospital onset COVID-19 infections (HOCIs) cannot always be readily identified based only on epidemiological data. Viral sequencing data provides additional information regarding potential transmission clusters, but the low mutation rate of SARS-CoV-2 can make interpretation using standard phylogenetic methods difficult.

Methods: We developed a novel statistical method and sequence reporting tool (SRT) that combines epidemiological and sequence data in order to provide a rapid assessment of the probability of HCAI among HOCI cases (defined as first positive test >48 hours following admission) and to identify infections that could plausibly constitute outbreak events. The method is designed for prospective use, but was validated using retrospective datasets from hospitals in Glasgow and Sheffield collected February-May 2020.

Results: We analysed data from 326 HOCIs. Among HOCIs with time-from-admission >8 days the SRT algorithm identified close sequence matches from the same ward for 160/244 (65.6%) and in the remainder 68/84 (81.0%) had at least one similar sequence elsewhere in the hospital, resulting in high estimated probabilities of within-ward and within-hospital transmission. For HOCIs with time-from-admission 3-7 days, the SRT probability of healthcare acquisition was >0.5 in 33/82 (40.2%).

Conclusions: The methodology developed can provide rapid feedback on HOCIs that could be useful for infection prevention and control teams, and warrants further prospective evaluation. The integration of epidemiological and sequence data is important given the low mutation rate of SARS-CoV-2 and its variable incubation period.

Funding: COG-UK HOCI funded by COG-UK consortium, supported by funding from UK Research and Innovation, National Institute of Health Research and Wellcome Sanger Institute.

Data availability

The sequence data analysed are included within publicly available datasets (https://www.cogconsortium.uk/data/), and a list of the relevant sequence identification codes is provided (Supplementary File 1). Due to data governance restrictions related to individual patient data linked to genetic sequences it is not possible to publicly share the associated meta-data. Requests for access to the data can be made by submission of a research proposal to the COG-UK Steering Committee (contact@cogconsortium.uk).

The following previously published data sets were used

Article and author information

Author details

  1. Oliver Stirrup

    Institute for Global Health, University College London, London, United Kingdom
    For correspondence
    oliver.stirrup@ucl.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8705-3281
  2. Joseph Hughes

    MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. Matthew Parker

    Sheffield Bioinformatics Core, The University of Sheffield, Sheffield, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. David G Partridge

    Directorate of Laboratory Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0417-2016
  5. James G Shepherd

    MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. James Blackstone

    The Comprehensive Clinical Trials Unit at UCL, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Francesc Coll

    Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. Alexander Keeley

    Sheffield Bioinformatics Core, The University of Sheffield, Sheffield, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  9. Benjamin B Lindsey

    Directorate of Laboratory Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4227-2592
  10. Aleksandra Marek

    Clinical Microbiology, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  11. Christine Peters

    Clinical Microbiology, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  12. Joshua B Singer

    MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  13. The COVID-19 Genomics UK (COG-UK) consortium

  14. Asif Tamuri

    Research Computing, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  15. Thushan I de Silva

    Directorate of Laboratory Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  16. Emma C Thomson

    Centre for Virus Research, MRC-University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  17. Judith Breuer

    Division of Infection and Immunity, University College London, London, United Kingdom
    For correspondence
    j.breuer@ucl.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8246-0534

Funding

COG-UK consortium

  • Oliver Stirrup

COG-UK consortium

  • Judith Breuer

The funders (MRC, NIHR and Wellcome) had no role in study design, data collection and interpretation, or the decision to submit the work for publication. Approval for publication was required from the Steering Group of the COG-UK consortium, which has funded the COG-UK HOCI study from their overarching project grant.

Ethics

Human subjects: Research Ethics for COG-UK Consortium and research undertaken under its auspices was granted by the PHE Research Ethics and Governance group as part of the emergency response to COVID-19 (24 April 2020, REF: R&D NR0195) and by the relevant Scottish biorepository authorities (16/WS/0207NHS and 10/S1402/33). This was a retrospective analysis on fully anonymized data, the collection of which did not involve any active research intervention. Consent therefore was neither required nor requested from individual patients.

Copyright

© 2021, Stirrup et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,440
    views
  • 145
    downloads
  • 26
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Oliver Stirrup
  2. Joseph Hughes
  3. Matthew Parker
  4. David G Partridge
  5. James G Shepherd
  6. James Blackstone
  7. Francesc Coll
  8. Alexander Keeley
  9. Benjamin B Lindsey
  10. Aleksandra Marek
  11. Christine Peters
  12. Joshua B Singer
  13. The COVID-19 Genomics UK (COG-UK) consortium
  14. Asif Tamuri
  15. Thushan I de Silva
  16. Emma C Thomson
  17. Judith Breuer
(2021)
Rapid feedback on hospital onset SARS-CoV-2 infections combining epidemiological and sequencing data
eLife 10:e65828.
https://doi.org/10.7554/eLife.65828

Share this article

https://doi.org/10.7554/eLife.65828

Further reading

    1. Epidemiology and Global Health
    2. Medicine
    3. Microbiology and Infectious Disease
    Edited by Diane M Harper et al.
    Collection

    eLife has published the following articles on SARS-CoV-2 and COVID-19.

    1. Medicine
    2. Microbiology and Infectious Disease
    3. Epidemiology and Global Health
    4. Immunology and Inflammation
    Edited by Jos WM van der Meer et al.
    Collection

    eLife has published articles on a wide range of infectious diseases, including COVID-19, influenza, tuberculosis, HIV/AIDS, malaria and typhoid fever.